Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: scott_jiminez who wrote (974)	2/3/2000 9:18:00 PM
From: Pseudo Biologist	Respond to of 4474

Any suggestions of problems with traffic jams in the ER? Not apparently. The figure that graces the A&B commentary, see below, suggests that this would not be a problem. They mention possible formation of "disallowed" aggregates, which induce apoptosis. Ariad's ones are apparently "allowed" aggregates, and these "preserve the normal function of the ER." Guess no bad traffic jams here. You are right that this is a full research article and comes with a nice commentary by M. Aridor and W.E. Balch of the Scripps Institute. The say that Ariad "capitalized on the recent realization that the ER can be induced to export a target protein." (work by Aridor and Balch, among others). One technical correction now that I read this a bit more (obvious to the cell biologists here): furin processing (cutting the desired protein out of the FKB12 mutant tandems) occurs in the Golgi. Richaard, who knows what the traders will do now, but apparently the day traders were all over this one today; just take a look at the intraday chart. PB